100 related articles for article (PubMed ID: 1588922)
1. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
Charleson S; Prasit P; Léger S; Gillard JW; Vickers PJ; Mancini JA; Charleson P; Guay J; Ford-Hutchinson AW; Evans JF
Mol Pharmacol; 1992 May; 41(5):873-9. PubMed ID: 1588922
[TBL] [Abstract][Full Text] [Related]
2. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.
Vickers PJ; Adam M; Charleson S; Coppolino MG; Evans JF; Mancini JA
Mol Pharmacol; 1992 Jul; 42(1):94-102. PubMed ID: 1635556
[TBL] [Abstract][Full Text] [Related]
3. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
[TBL] [Abstract][Full Text] [Related]
4. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ
Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
Gupta N; Nicholson DW; Ford-Hutchinson AW
Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
Ferguson AD; McKeever BM; Xu S; Wisniewski D; Miller DK; Yamin TT; Spencer RH; Chu L; Ujjainwalla F; Cunningham BR; Evans JF; Becker JW
Science; 2007 Jul; 317(5837):510-2. PubMed ID: 17600184
[TBL] [Abstract][Full Text] [Related]
7. Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.
Vickers PJ; Adam M; Charleson S; Abramovitz M; O'Neill G; Mancini JA
J Lipid Mediat; 1993; 6(1-3):31-42. PubMed ID: 8357989
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.
Martel-Pelletier J; Mineau F; Fahmi H; Laufer S; Reboul P; Boileau C; Lavigne M; Pelletier JP
Arthritis Rheum; 2004 Dec; 50(12):3925-33. PubMed ID: 15593193
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein.
Charleson S; Evans JF; Léger S; Perrier H; Prasit P; Wang Z; Vickers PJ
Eur J Pharmacol; 1994 May; 267(3):275-80. PubMed ID: 8088366
[TBL] [Abstract][Full Text] [Related]
10. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.
Macdonald D; Brideau C; Chan CC; Falgueyret JP; Frenette R; Guay J; Hutchinson JH; Perrier H; Prasit P; Riendeau D; Tagari P; Thérien M; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Mar; 18(6):2023-7. PubMed ID: 18276139
[TBL] [Abstract][Full Text] [Related]
11. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
[TBL] [Abstract][Full Text] [Related]
12. 5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).
Hutchinson JH; Li Y; Arruda JM; Baccei C; Bain G; Chapman C; Correa L; Darlington J; King CD; Lee C; Lorrain D; Prodanovich P; Rong H; Santini A; Stock N; Prasit P; Evans JF
J Med Chem; 2009 Oct; 52(19):5803-15. PubMed ID: 19739647
[TBL] [Abstract][Full Text] [Related]
13. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
Dixon RA; Diehl RE; Opas E; Rands E; Vickers PJ; Evans JF; Gillard JW; Miller DK
Nature; 1990 Jan; 343(6255):282-4. PubMed ID: 2300173
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000
[TBL] [Abstract][Full Text] [Related]
15. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein.
Hatzelmann A; Goossens J; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1994 Jun; 47(12):2259-68. PubMed ID: 8031320
[TBL] [Abstract][Full Text] [Related]
16. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
[TBL] [Abstract][Full Text] [Related]
17. 5-lipoxygenase-activating protein is an arachidonate binding protein.
Mancini JA; Abramovitz M; Cox ME; Wong E; Charleson S; Perrier H; Wang Z; Prasit P; Vickers PJ
FEBS Lett; 1993 Mar; 318(3):277-81. PubMed ID: 8440384
[TBL] [Abstract][Full Text] [Related]
18. FLAP inhibitors for the treatment of inflammatory diseases.
Sampson AP
Curr Opin Investig Drugs; 2009 Nov; 10(11):1163-72. PubMed ID: 19876784
[TBL] [Abstract][Full Text] [Related]
19. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Matzke M; Pleiss U; Keldenich J; Müller-Peddinghaus R
Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():23-31. PubMed ID: 7771337
[No Abstract] [Full Text] [Related]
20. Pharmacological modulation of human platelet leukotriene C4-synthase.
Sala A; Folco G; Henson PM; Murphy RC
Biochem Pharmacol; 1997 Mar; 53(6):905-8. PubMed ID: 9113110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
